Understand the source comparison
Best Research Peptides for Rheumatoid Arthritis: Feature Comparison
Understanding how research peptides differ in mechanism, administration, and evidence base helps researchers and clinicians select compounds aligned with specific study objectives or patient profiles. BPC-157 NF-κB inhibition, angiogenesis, collagen synthesis
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Understanding how research peptides differ in mechanism, administration, and evidence base helps researchers and clinicians select compounds aligned with specific study objectives or patient profiles.
- BPC-157
- NF-κB inhibition, angiogenesis, collagen synthesis
- Subcutaneous, oral
- High. Multiple RA models show 50–62% reduction in joint swelling
- Only peptide with published gut barrier repair + joint protection data
- Best first-choice research peptide for RA due to dual anti-inflammatory and regenerative profile
- TB-500
- VEGF upregulation, fibroblast activation, MMP modulation
- Subcutaneous
- Moderate. Cartilage protection shown in adjuvant arthritis models
- Strongest angiogenic signal; ideal for erosive disease
- Pairs well with BPC-157 for combined inflammation control and tissue repair
- Thymosin Alpha-1
- Treg modulation, dendritic cell maturation
- Moderate. Autoimmune hepatitis and viral studies; limited RA-specific data
- Only peptide targeting immune tolerance rather than suppression
- Consider for patients with autoantibody-driven disease or failed DMARD response
- GHRP-2
- Growth hormone secretagogue, IGF-1 elevation
- Low. No direct RA studies; GH/IGF-1 effects on cartilage well-documented
- Hormonal approach to cartilage repair; systemic effects
- Use cautiously; requires monitoring for GH-related side effects
- MK-677
- Oral GH secretagogue, IGF-1 elevation
- Oral
- Low. Popular in muscle wasting research; no RA trials
- Oral bioavailability advantage
- Convenient but less targeted than injectable peptides